Amneal Pharmaceuticals In... (AMRX)
NYSE: AMRX
· Real-Time Price · USD
7.16
-0.03 (-0.42%)
At close: May 23, 2025, 3:59 PM
7.16
0.07%
After-hours: May 23, 2025, 04:12 PM EDT
-0.42% (1D)
| Bid | 7.12 |
| Market Cap | 3.33B |
| Revenue (ttm) | 2.83B |
| Net Income (ttm) | -13.05M |
| EPS (ttm) | -0.04 |
| PE Ratio (ttm) | -178.87 |
| Forward PE | 8.75 |
| Analyst | Buy |
| Ask | 7.18 |
| Volume | 834,841 |
| Avg. Volume (20D) | 2,068,403 |
| Open | 7.05 |
| Previous Close | 7.19 |
| Day's Range | 7.08 - 7.18 |
| 52-Week Range | 6.29 - 9.47 |
| Beta | 1.17 |
About AMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+2.04%
Ameal Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
3 weeks ago
+2.97%
AMRX stock has given up its prior gain. Amneal Pharmaceuticals shares were trading higher after the company reported better-than-expected Q1 adjusted EPS results and issued FY25 sales guidance with its midpoint above estimates.
3 weeks ago · seekingalpha.com
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call TranscriptAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Off...
